EGFR T790M resistance mutation in non small-cell lung carcinoma

Clinica Chimica Acta

Volumn 444, Issue , 2015, Pages 81-85

  Denis, Marc G ^a   Vallée, Audrey ^a   Théoleyre, Sandrine ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

EGFR; Mutation; Non small cell lung cancer; Resistance; T790M

Indexed keywords

AZD 9291; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ROCILETINIB; THIRD GENERATION EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED RESISTANCE MUTATION; ACTIVATING MUTATION; AMINO ACID SUBSTITUTION; CANCER SURVIVAL; DNA SEQUENCE; DRUG EXPOSURE; DRUG RESPONSE; EGFR GENE; EXON 20 INSERTION; FALSE POSITIVE RESULT; GENE AMPLIFICATION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; HUMAN; MASS SPECTROMETRY; MUTATION RATE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY RESISTANCE; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; SOMATIC MUTATION; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; MUTATION;

PYRONIA TITHONUS;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84923011927     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.01.039     Document Type: Review

References (67)

1. Mok T.S., Wu Y.-L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
2. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
3. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
4. Han J.Y., Park K., Kim S.W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
5. Zhou C., Wu Y.-L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
6. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
7. Sequist L.V., Yang J.C.-H., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
8. Wu Y.L., Zhou C., Hu C.P., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:213-222.
9. Vallee A., Sagan C., Le Loupp A.G., Bach K., Dejoie T., Denis M.G. Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol 2013, 43:1045-1051.
10. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
11. Beau-Faller M., Prim N., Ruppert A.M., et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2014, 25:126-131.
12. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
13. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
14. He M., Capelletti M., Nafa K., et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012, 18:1790-1797.
15. Kancha R.K., von Bubnoff N., Peschel C., Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009, 15:460-467.
16. Masago K., Fujita S., Irisa K., et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC>ATC in exon 20 (S768I). Jpn J Clin Oncol 2010, 40:1105-1109.
17. Kobayashi S., Canepa H.M., Bailey A.S., et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013, 8:45-51.
18. Querings S., Altmuller J., Ansen S., et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 2011, 6:e19601.
19. Takano T., Ohe Y., Tsuta K., et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 2007, 13:5385-5390.
20. Do H., Krypuy M., Mitchell P., Fox S., Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142.
21. Fukui T., Ohe Y., Tsuta K., et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4751-4757.
22. Didelot A., Le Corre D., Luscan A., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012, 92:275-280.
23. Kimura H., Kasahara K., Kawaishi M., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.
24. Vallee A., Le Loupp A.G., Denis M.G. Efficiency of the therascreen(R) RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clin Chim Acta 2013, 429C:8-11.
25. Lin C.-H., Yeh K.-T., Chang Y.-S., Hsu N., Chang J.-G. Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. J Biomed Sci 2010, 17:37.
26. Dufort S., Richard M.-J., Lantuejoul S., de Fraipont F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011, 30:57.
27. Ellison G., Donald E., McWalter G., et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010, 29:132-139.
28. Goto K., Satouchi M., Ishii G., et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012, 23:2914-2919.
29. Ellison G., Zhu G., Moulis A., Dearden S., Speake G., McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013, 66:79-89.
30. Arcila M.E., Nafa K., Chaft J.E., et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013, 12:220-229.
31. Oxnard G.R., Lo P.C., Nishino M., et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013, 8:179-184.
32. Yasuda H., Kobayashi S., Costa D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012, 13:e23-e31.
33. Wu J.Y., Yu C.J., Chang Y.C., Yang C.H., Shih J.Y., Yang P.C. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011, 17:3812-3821.
34. Wu J.-Y., Wu S.-G., Yang C.-H., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008, 14:4877-4882.
35. Sos M.L., Rode H.B., Heynck S., et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010, 70:868-874.
36. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105:2070-2075.
37. Girard N., Lou E., Azzoli C.G., et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010, 16:755-763.
38. Bell D.W., Gore I., Okimoto R.A., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005, 37:1315-1316.
39. Oxnard G.R., Miller V.A., Robson M.E., et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012, 7:1049-1052.
40. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
41. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
42. Su K.Y., Chen H.Y., Li K.C., et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012, 30:433-440.
43. Yu H.A., Arcila M.E., Hellmann M.D., Kris M.G., Ladanyi M., Riely G.J. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014, 25:423-428.
44. Sakai K., Horiike A., Irwin D.L., et al. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci 2013, 104:1198-1204.
45. Nakamura T., Sueoka-Aragane N., Iwanaga K., et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011, 6:1639-1648.
46. Rosell R., Molina M.A., Costa C., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17:1160-1168.
47. Costa C., Molina M.A., Drozdowskyj A., et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014, 20:2001-2010.
48. Fujita Y., Suda K., Kimura H., et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012, 7:1640-1644.
49. Williams C., Ponten F., Moberg C., et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999, 155:1467-1471.
50. Marchetti A., Felicioni L., Assessing Buttitta F., EGFR Mutations. N Engl J Med 2006, 354:526-528.
51. Do H., Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem 2015, 61:64-71.
52. Ye X., Zhu Z.Z., Zhong L., et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?. J Thorac Oncol 2013, 8:1118-1120.
53. Do H., Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget 2012, 3:546-558.
54. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3. [75ra26].
55. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
56. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
57. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
58. Kuiper J.L., Heideman D.A., Thunnissen E., et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014, 85:19-24.
59. Watanabe S., Tanaka J., Ota T., et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011, 11:1.
60. Li W., Ren S., Li J., et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014, 84:295-300.
61. Cross D.A., Ashton S.E., Ghiorghiu S., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014, 4:1046-1061.
62. Finlay M.R., Anderton M., Ashton S., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014, 57:8249-8267.
63. Tjin Tham Sjin R., Lee K., Walter A.O., et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther 2014, 13:1468-1479.
64. Luo J., Shen L., Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 2014, 4:6269.
65. Douillard J.Y., Ostoros G., Cobo M., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014, 110:55-62.
66. Vallee A., Marcq M., Bizieux A., et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer 2013, 82:373-374.
67. Marcq M., Vallee A., Bizieux A., Denis M.G. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?. J Thorac Oncol 2014, 9:e49-e50.